Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Trimmed by Wells Fargo & Company MN

Wells Fargo & Company MN cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 3.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,279 shares of the company’s stock after selling 1,524 shares during the quarter. Wells Fargo & Company MN owned 0.05% of Nurix Therapeutics worth $740,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock valued at $1,531,000 after acquiring an additional 31,352 shares in the last quarter. Barclays PLC raised its stake in Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock valued at $2,884,000 after purchasing an additional 56,190 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock valued at $14,869,000 after purchasing an additional 235,971 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Nurix Therapeutics in the fourth quarter worth $1,026,000. Finally, Norges Bank purchased a new position in shares of Nurix Therapeutics during the fourth quarter valued at $6,006,000.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Wells Fargo & Company reduced their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Morgan Stanley boosted their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, February 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday. Finally, Leerink Partners started coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They set a “market perform” rating and a $16.00 target price for the company. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $30.44.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $11.16 on Friday. The stock has a market capitalization of $850.79 million, a P/E ratio of -3.86 and a beta of 2.23. The business has a 50-day moving average of $12.13 and a two-hundred day moving average of $18.08. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same period in the previous year, the company earned ($0.76) EPS. As a group, research analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,438 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $28,037.00. Following the transaction, the chief financial officer now owns 39,922 shares in the company, valued at $459,103. This trade represents a 5.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,377 shares of the business’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider now directly owns 61,516 shares of the company’s stock, valued at approximately $707,434. This represents a 5.20 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,640 shares of company stock worth $151,277. 7.40% of the stock is owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.